GLOBEALERT
Sign in
The wire

Feed

Open sources, classified and cross-checked. 25,993+ stories.

AllConflictMilitaryPoliticsBusinessSci & TechCyberDisasterHealthWorld
24h3 days7 days30 daysAll·All regionsNorth AmericaSouth AmericaWestern EuropeEastern EuropeBalticsMiddle EastNorth AfricaSub-Saharan AfricaSouth AsiaEast AsiaOceania
DisasterBreakingOct 30Breaking news and reactions following the Urda train accident, live | The Institute of Legal Medicine of Toledo has already received 69 bodies and performed 48 autopsiesEl País
PoliticsOct 30Election staff in Vijayawada can vote by postal ballot till 5 p.m. on October 30Election Observer S. Nagalakshmi inspects the postal ballot centre at MogalrajpuramThe Hindu
PoliticsOct 30French minister warns of 'very high' violence risk as country braces for Halloween protestsFrance will deploy some 70,000 police officers in Paris and other cities ahead of a new round of nationwide protests on Saturday, with Interior Minister Laurent Nuñez warning of a "very high risk of public disorder". The minister pledged an "extremely firm" response after mass protests on October 17 degenerated into rioting and looting.France 24 [en]
WorldOct 30Court orders Erin Patterson never to be released from prison for mushroom poisoningsAn Australian appeals court has ordered triple-murderer Erin Patterson to never be released from prison because of the “shocking criminality” involved in poisoning four of her estranged husband’s relatives with death cap mushroomsABC News
PoliticsOct 30CPI(M) has no links with online attacks against Mammootty, says M.V. GovindanSFI and DYFI have won a lot of nationwide approval in the fight against Chief Election Commissioner Gyanesh Kumar. In that context, there is no reason to decide not to visit Mammootty, says GovindanThe Hindu
BusinessOct 30Steve Jobs, Apple founder: "Deciding what not to do is as important as deciding what to do"La reflexión del empresario apunta al valor de elegir las prioridades y dejar de lado aquello que desvía la atención de los objetivos principales.Clarín
BusinessOct 30French economy contracts 0.1% in third quarterDespite the weakness in the Eurozone’s second-largest economy, growth in the 21-country bloc was better than expectedFinancial Times
BusinessOct 30Pinnacle Bank reports Q3 resultsPinnacle Bank has released its financial results for the third quarter. This indicates a routine business update on the bank's performance.Seeking Alpha Tech
PoliticsOct 30Seeman hints at contesting in Ambasamudram bypollThe NTK chief says his party will launch its byelection campaign from Palayamkottai on November 26, the birthday of the slain LTTE leader Velupillai PrabhakaranThe Hindu
MilitaryOct 30Russia’s Next Mobilization Is Already HappeningWith military recruitment falling short, the Kremlin has switched to stealth and coercion.Foreign Policy
PoliticsOct 30Swedish academic says denied entry to UK over Palestine eventHome Office cancels Andreas Malm's planned travel to the UK, saying his presence 'not conducive to the public good'.Al Jazeera [en]
BusinessOct 30First Northern Community Bancorp reports Q3 resultsFirst Northern Community Bancorp has reported its financial results for the third quarter. This is a standard business announcement regarding the company's financial performance.Seeking Alpha Tech
PoliticsOct 30Security guard who protected Nigel Farage on campaign trail was facing rape chargeReform UK says guard’s services were supplied by a third-party contractor who had assured them he had been vettedIrish Times World
BusinessOct 30Sanofi beats top-line and bottom-line estimates; raises FY26 outlookSanofi has surpassed both its top-line and bottom-line financial estimates. The company has also increased its fiscal year 2026 outlook.Seeking Alpha Tech
Sci & TechOct 30The Air Force's SR-71 Blackbird, capable of reaching Mach 3, ran on a fuel so stable that a match could be put out in it. Then they had to invent a way to light it.The so-called JP-7 made possible the emergence of the world's fastest manned aircraft. It was a challenge for the fuel to withstand the heat and friction of speed.Clarín
DisasterOct 30Survivors of Spain’s worst train crashes urge action after latest disasterAs people suffering post-traumatic stress watch history repeat itself, experts call for investment in safety.Al Jazeera [en]
BusinessOct 30France's economy shrinks 0.1% in Q3 as exports declineFrance's economy saw a 0.1% contraction in the third quarter of the year. This decline is attributed to a decrease in exports.Seeking Alpha Tech
ConflictOct 30Russian strikes on Kyiv kill one, injure another, damage homes and businessesUkrinform [en]
BusinessOct 30Digital Realty targets $8.30-$8.35 2026 core FFO per share as $2.5B backlog lifts confidence into 2027Digital Realty is targeting $8.30-$8.35 for its 2026 core FFO per share. A $2.5 billion backlog is contributing to increased confidence for the company's outlook into 2027.Seeking Alpha Tech
PoliticsOct 30Who pays for a $1 bil riot? Europe looks past rioters to their parents and the apps in their pocketsIn France, the bill for a riot could soon be paid from a family’s housing aid. Some people in a violent crowd could be made to pay for…Japan Today
WorldOct 30Okawara Kako Corporation wrongful conviction, why did the judge deny bail? 'Fear of evidence destruction'A judge denied bail in a wrongful conviction case, citing the risk of evidence destruction. This raises questions about judicial decisions and the justice system.Asahi Shimbun
HealthOct 30Junshi Biosciences Announces the Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS207 in Combination withJS007 for the First-Line Treatment of Advanced Hepatocellular Carcinoma SHANGHAI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the first patient dosing has been completed in a multi-center, randomized, controlled, and open-label phase 3 clinical study evaluating the efficacy and safety of the company's product, recombinant humanized anti-PD-1/VEGF bispecific antibody (code: JS207), in combination with recombinant humanized anti-CTLA-4 monoclonal antibody (code: JS007) compared to toripalimab in combination with bevacizumab for the first-line treatment of advanced hepatocellular carcinoma (JS207-017-III-HCC Study, NCT07823348). Liver cancer is a common malignant tumor of the digestive system worldwide, with hepatocellular carcinoma (HCC) being the main pathological type (accounting for approximately 90%). China bears an exceptionally heavy disease burden of liver cancer. According to statistics of GLOBOCAN 2024, there were approximately 354,100 new liver cancer cases and 303,800 liver cancer deaths in China in 2024, making it the second leading cause of cancer-related death after lung cancer. Due to its insidious onset, over 50% of patients are diagnosed at an intermediate or advanced stage. Systemic therapy is an important treatment modality for intermediate and advanced liver cancer, which primarily includes molecular targeted drugs, immunotherapy and systemic chemotherapy. However, as the median overall survival of current first-line systemic therapies is less than 2 years, there remain substantial unmet clinical needs for patients with intermediate and advanced liver cancer. In October 2026, the results of a phase 2 clinical study of JS207 in combination with JS007 for the first-line treatment of advanced HCC were presented at the European Society for Medical Oncology (ESMO) Congress 2026 (Abstract No.: #1693eP). The study results showed that the drug combination therapy exhibited robust anti-tumor activity. A total of 36 patients received treatment of JS207 in combination with JS007 (3 mg/kg Q6W for two cycles, and 1 mg/kg Q6W (i.e. recommended dose) thereafter). Among 34 efficacy-evaluable patients, the objective response rate (ORR) of combined treatment reached 44.1%, the disease control rate (DCR) reached 85.3%, the median progression-free survival (PFS) had not yet been reached, and the six-month PFS rate reached 67%. The drug combination therapy was well tolerated. JS207-017-III-HCC study is a multi-center, randomized, controlled, open-label phase 3 clinical study. The study aims to evaluate the efficacy and safety of JS207 in combination with JS007 compared to toripalimab in combination with bevacizumab for the first-line treatment of advanced hepatocellular carcinoma. This study plans to enroll 560 subjects, and the primary endpoints are PFS and overall survival (OS). About JS207 JS207 is a recombinant humanized anti-PD-1/VEGF bispecific antibody self-developed by Junshi Biosciences, mainly used for the treatment of advanced malignant tumors. JS207 can simultaneously bind to PD-1 and VEGFA with high affinity, effectively block the binding of PD-1 to PD-L1 and PD-L2, and inhibit the binding of VEGF to its receptor. JS207 has the efficacy properties of both immunotherapeutic drugs and anti-angiogenic drugs. Through the neutralization of VEGF, JS207 inhibits the proliferation of vascular endothelial cells, improves the tumor microenvironment and increases the infiltration of cytotoxic T lymphocytes in the tumor microenvironment, thereby achieving better anti-tumor activity. JS207 is designed based on the high-affinity, clinically proven and differentiated anti-PD-1 drug toripalimab as the backbone. The anti-PD-1 moiety of JS207 adopts a Fab structure to maintain binding affinity to PD-1 and thereby attain better enrichment in the tumor microenvironment. The anti-VEGF moiety has a binding affinity for human vascular endothelial growth factor that is comparable to that of bevacizumab. In non-clinical in vitro cytological tests, compared with the combination of an anti-PD-1/PD-L1 monoclonal antibody and a VEGF monoclonal antibody, a bispecific antibody simultaneously targeting PD-1/PD-L1 and VEGF demonstrated significantly enhanced PD-1 antigen binding and internalization, and synergistic enhancement of the NFAT signaling pathway, thereby better activating immune cells in the tumor microenvironment. About JS007 JS007 is a recombinant humanized anti-CTLA-4 monoclonal antibody injection self-developed by the Company, mainly used for the treatment of advanced malignant tumors. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is an important receptor for T cell surface modulates immune response. Studies have shown that JS007 is able to bind to CTLA-4 specifically and block the interaction between CTLA-4 and its ligand B7 (CD80 or CD86) effectively, thereby activates T-lymphocyte and inhibits the growth of tumor. About Junshi Biosciences Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. With our outstanding capacity for innovative drug discovery, strong biotechnology R&D capability, and large-scale production capacity, we have successfully developed a drug candidate portfolio with global competitiveness and a well-structured research pipeline, which covers therapeutic areas including cancer, autoimmune, metabolic, and infectious diseases. Our innovative field spans cutting-edge therapeutic modalities, including mAbs, small-molecule drugs, ADCs, bsAb/msAb, fusion proteins, nucleic acid drugs and vaccines. Five of the company's products have received marketing authorizations in China and international markets, one of which is toripalimab, China's domestically developed anti-PD-1 monoclonal antibody. Toripalimab has been approved in over 50 countries and regions including China, the US, and Europe. With a mission of "providing patients with world-class, trustworthy, affordable, and innovative drugs," Junshi Biosciences is "In China, For Global." The company currently employs more than 3,000 people worldwide. Headquartered in Shanghai, China, it has a business presence in multiple countries and regions around the world. For more information, please visit: http://www.junshipharma.com. Copyright 2026 GlobeNewswire, Inc.riauone · indonesia
DisasterOct 30Wildfire smoke killed estimated 3,560 people in Indonesia in September: StudyJAKARTA: Smoke from months of wildfires across Indonesia caused an estimated 3,560 deaths in September, twice the August estimate, according to a new study by a Helsinki-based thin...kuwaittimes · kuwait
DisasterOct 30Fire pollution killed 3,560 people in Indonesia in September, report saysThe same month, about 57.8 million people in Indonesia were inhaling unhealthy to hazardous air, according to a new study.japantimes · japan
← NewerOlder →